Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:17:16.812Z.
Consensus retrieved: 2026-10-06T13:18:27.404Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:16.812Z.
Quote observation: 2026-10-06T14:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23bdec7124bcf20b562f8235598f93689ea1cbdfcf2aa7384f68a4c8921eaa93
Forward PE Ratio (N/A) = Dated Quote Price ($102.94) / Consensus Forward EPS ($-3.85)
FORWARD PE RATIO
N/A
Kymera Therapeutics, Inc.
Market Cap
$8.47B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.47B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $8.45B | 257.59 |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 16.98 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.54B | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.74B | N/A |
| Bruker Corporation (BRKRP)vs › | $9.04B | 212.28 |
| Insulet Corp. (PODD)vs › | $9.31B | 20.66 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.62B | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.59B | 19.23 |
| Bruker Corporation (BRKR)vs › | $9.34B | 28.93 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $102.94, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.85 | $-4.29 – $-3.14 | 16 | n/m |
| 2027-12-31 | $-5.11 | $-6.36 – $-3.94 | 16 | n/m |
| 2028-12-31 | $-5.49 | $-6.56 – $-4.25 | 15 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
